View : 705 Download: 0

Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial

Title
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial
Authors
Han, Sang WonKim, Yong-JaeAhn, Seong HwanSeo, Woo-KeunYu, SungwookOh, Seung-HunKim, Youn NamLee, Kyung-YulMAESTRO Study Investigators
Ewha Authors
김용재
SCOPUS Author ID
김용재scopus
Issue Date
2016
Journal Title
INTERNATIONAL JOURNAL OF STROKE
ISSN
1747-4930JCR Link

1747-4949JCR Link
Citation
INTERNATIONAL JOURNAL OF STROKE vol. 11, no. 4, pp. 485 - 491
Keywords
Antiplateletclopidogrelcytochrome P450 2C19preventiontriflusalstroke
Publisher
SAGE PUBLICATIONS LTD
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Rationale and aim The antiplatelet effect of clopidogrel is reportedly influenced by cytochrome P450 2C19 (CYP2C19) polymorphisms. However, there is no data concerning the relationship between stroke recurrence and CYP2C19 polymorphisms in patients treated with clopidogrel for secondary prevention of ischemic stroke. Triflusal may be an alternative therapy for clopidogrel in patients with poor genotype. The Comparison of Triflusal and Clopidogrel Effects in Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping (MAESTRO) study will investigate the effect of antiplatelet agents based on CYP2C19 polymorphisms in secondary prevention of ischemic stroke. Sample size and design Assuming that 55% of patients belong to the poor genotype group, the required sample size is 1080 patients with at least 24 months of follow-up. This study is designed as a prospective, multicenter, randomized, parallel-group, open-label, and blind genotype trial. Patients who experience their first non-cardiogenic ischemic stroke within 30 days prior to screening are eligible. Patients received 300mg triflusal twice a day or 75mg clopidogrel once daily during the trial. The study is registered with ClinicalTrials.gov (NCT01174693). Study outcome The primary outcome is recurrent ischemic stroke or hemorrhagic stroke. Secondary outcomes consist of composite major vascular events including stroke, myocardial infarction, coronary revascularization, or vascular death. Discussion Personalized medicine may be essential for patients according to individual drug metabolism abilities. MAESTRO is the first prospective study designed to evaluate the effect of CYP2C19 polymorphism in secondary stroke prevention and will resolve several questions regarding preventive antiplatelet agents for recurrent stroke.
DOI
10.1177/1747493015620804
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE